India, June 30 -- Philip Morris International Inc. (PM) announced that the U.S. Food and Drug Administration (FDA) has issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products, marking the first time nicotine pouches have received such authorization.
FDA Authorization
The MRTP orders allow PMI U.S. to market the claim: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."
Stacey Kennedy, CEO of PMI U.S., said the decision provides adult nicotine consumers with science-based information and reinforces FDA's evidence-driven approach to evaluating products across the continuum of risk.
Product Portfolio
The...